- Home
- CRDF vs PCK Comparison
CRDF vs PCK Comparison
Compare CRDF & PCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- PCK
- Stock Information
- Founded
- CRDF 1999
- PCK 2002
- Country
- CRDF United States
- PCK United States
- Employees
- CRDF N/A
- PCK N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- PCK Trusts Except Educational Religious and Charitable
- Sector
- CRDF Health Care
- PCK Finance
- Exchange
- CRDF Nasdaq
- PCK Nasdaq
- Market Cap
- CRDF 196.2M
- PCK 172.2M
- IPO Year
- CRDF N/A
- PCK N/A
- Fundamental
- Price
- CRDF $2.66
- PCK $5.57
- Analyst Decision
- CRDF Strong Buy
- PCK
- Analyst Count
- CRDF 4
- PCK 0
- Target Price
- CRDF $12.25
- PCK N/A
- AVG Volume (30 Days)
- CRDF 1.1M
- PCK 79.7K
- Earning Date
- CRDF 05-08-2025
- PCK 01-01-0001
- Dividend Yield
- CRDF N/A
- PCK 4.58%
- EPS Growth
- CRDF N/A
- PCK N/A
- EPS
- CRDF N/A
- PCK N/A
- Revenue
- CRDF $587,000.00
- PCK N/A
- Revenue This Year
- CRDF N/A
- PCK N/A
- Revenue Next Year
- CRDF N/A
- PCK N/A
- P/E Ratio
- CRDF N/A
- PCK N/A
- Revenue Growth
- CRDF N/A
- PCK N/A
- 52 Week Low
- CRDF $2.01
- PCK $4.85
- 52 Week High
- CRDF $5.64
- PCK $6.33
- Technical
- Relative Strength Index (RSI)
- CRDF 42.40
- PCK 53.74
- Support Level
- CRDF $2.42
- PCK $5.50
- Resistance Level
- CRDF $2.87
- PCK $5.60
- Average True Range (ATR)
- CRDF 0.19
- PCK 0.07
- MACD
- CRDF 0.01
- PCK 0.03
- Stochastic Oscillator
- CRDF 27.91
- PCK 86.76
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About PCK Pimco California Municipal Income Fund II of Beneficial Interest
PIMCO CA Muni Income Fund II is a closed-ended investment company. Its investment objective is to seek to provide current income exempt from federal and California income tax. The company portfolio of investment comprises of different sector investments such as healthcare, education, property, and others.